The opioid epidemic: what needs to change





DR CHRIS HAYES
HUNTER INTEGRATED PAIN SERVICE

Disclosures

- Earlier career, pharma sponsored teaching and consultancy: pre 2013
- Public hospital system
- Hunter Integrated Pain Service: Brainman, website
- Past Dean Faculty of Pain Medicine ANZCA
- Other organisations: Painaustralia, NSW Agency for Clinical Innovation, National Prescribing Service, Therapeutic Guidelines





Reconsidering opioid therapy

Health Professional Resources Hunter Integrated Pain Service May 2014


A Hunter New England Perspective

Existing evidence does not support the long term efficacy and safety of opioid therapy for chronic non-cancer pain

- 1. Indications: Current evidence based indications for opioid therapy are:
 - i. Acute pain
 - ii. Cancer pain
 - iii. Palliative or "comfort" care
 - iv. Opioid dependency / addiction


Outline

- Models of care
- Evidence
- Guidelines
- Implementation, including indications & zones on clinical uncertainty
- Advocacy
- Regulation




Biopsychosocial model

G Engel 1977



"Sociopsychobiomedical" Inverting BPS, FPM ANZCA 2015 Whole person approach




White R, Hayes C. "Brainman" story. J Pain Research 2016

Mechanisms contributing to pain



IASP 2017 Nociplastic pain




Sensitisation (nociplastic)

Nerve injury (neuropathic)

Tissue injury (nociceptive)

Behaviour change wheel





Evidence





Research


JAMA | Original Investigation


Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain The SPACE Randomized Clinical Trial

Erin E. Krebs, MD, MPH; Amy Gravely, MA; Sean Nugent, BA; Agnes C. Jensen, MPH; Beth DeRonne, PharmD; Elizabeth S. Goldsmith, MD, MS; Kurt Kroenke, MD; Matthew J. Bair; Siamak Noorbaloochi, PhD

- Pragmatic RCT opioid v non-opioid analgesics for 1 year in primary care
- 240 VA patients: mod severe chronic back pain or knee/hip OA, not on opioids
- Mean pain intensity initially 5.4 in both arms
- Pain scores at 1 year worse in opioid arm (4.0) than non-opioid (3.5) (P=0.034)
- Pain interference no different, adverse effects worse in opioid group (P=0.03)

Space results







PAIN





Changes in pain intensity after discontinuation of long-term opioid therapy for chronic noncancer pain

Sterling McPherson^{a,b,c}, Crystal Lederhos Smith^{a,b}, Steven K. Dobscha^{d,e}, Benjamin J. Morasco^{d,e}, Michael I. Demidenko^d, Thomas H.A. Meath^{d,f}, Travis I. Lovejoy^{d,e,g,*}

Abstract

Little is known about changes in pain intensity that may occur after discontinuation of long-term opioid therapy (LTOT). The objective of this study was to characterize pain intensity after opioid discontinuation over 12 months. This retrospective U.S. Department of

- Surveyed 551 VA patients, long-term opioid therapy for CNCP for ≥ 1 year before discontinuing
- 87% musculoskeletal pain, 11% headache pain including migraines, 6% neuropathic pain

Discontinuation results





Figure 1. Average within-individual pain intensity numeric rating scale score medians, minimums, maximums, and interquartile ranges prediscontinuation and postdiscontinuation periods.



Guidelines: Opioids & CNCP





- FPM ANZCA 2015
 - Opioids cannot be considered a core component of CNCP management
 - Traffic lights 40 & 100mg
 - Given widespread prescription the following principles are offered ...
- US Centres for Disease Control & Prevention 2016
 - Non-pharmacological & non-opioid treatments preferred
 - Traffic lights 50 and 90mg oMEDD
 - Consider opioids only if expected benefits outweigh risks
- UK National Institute for Health & Care Excellence: Guideline for LBP and sciatica 2016
 - Do not offer opioids for chronic low back pain




Implementation






Opioid indications (HIPS)

- Acute pain (RCTs)
- Cancer pain (SR)
- Palliative care (SR)
- Opioid dependency (SR)



Zones of clinical uncertainty (HIPS)

- Acute pain: duration of opioid treatment in complex cases
- Cancer pain: long term survivors
- Palliative care: when does older person become palliative?
- Opioid dependency: overlap with chronic pain



Opioid recommendations (HIPS)



- Opioids are no longer indicated for CNCP
- Have a conversation about opioid weaning
- Negotiate rate of reduction with patient; "would you like a faster or slower wean?"
- Standard approach: monthly step down by 10 -25% of starting dose

HIPS 2018 annual report

Table 13 Medication use — Change from referral to episode end

Medication use (v1 and v2 data)	HIPS		All Services	
	Referral	Episode end	Referral	Episode end
Percent using opioids >2 days/week (n=61, 2318)*	55.7	42.6	52.7	43.7
Ave oMEDD (mg) ^ (n=36, 1162)*	43.8	21.4	57.0	41.7
Ave number of major drug groups (n=61, 2524)*	2.9	2.2	2.4	2.2



HIPS 2018 annual report

Patients making clinically significant improvements from referral to episode end

HIPS	Domain	All services
27.0% (17 patients)	Average pain rating	33.4% (1365 patients)
60.9% (42 patients)	Pain interference	64.6% (2945 patients)
62.2% (28 patients)	Depression	61.6% (1820 patients)
42.1% (16 patients)	Anxiety	46.8% (1209 patients)
55.3% (21 patients)	Stress	62.6% (1609 patients)
56.1% (32 patients)	Pain catastrophising	58.1% (1879 patients)
63.6% (35 patients)	Pain self-efficacy	52.5% (2069 patients)

Note: reported for patients experiencing at least moderate symptoms at referral. See Section 2.1.2 for more information.



Prescribing wellness: comprehensive pain management outside specialist services

SUMMARY

Opioids have important roles in the time-limited treatment of acute and cancer pain, end-of-life pain or dyspnoea, and in opioid dependency.

Maintaining focus on biomedical treatments, including drugs, has limited success in chronic pain.

Active self-management and healthy lifestyle choices are fundamental to addressing multisystem complexity and harnessing neuroplasticity in chronic pain.

Addressing psychosocial maladaptations and physical deconditioning requires a variety of approaches, frequently involving multiple care providers.

In practice, most pain care is delivered outside specialist centres by GPs and other non-pain specialists. Although they are well placed to provide multimodal care, they often lack training and confidence in delivering this care.



Simon Holliday Staff specialist¹ General practitioner²

Chris Hayes Specialist pain medicine physician³

Lester Jones

Pain educator and PhD candidate⁴

Jill Gordon

Associate professor in medical education (retired)⁵ General practitioner⁶

Newman Harris

Consultant psychiatrist and Specialist pain medicine

Advocacy





AUSTRALIAN NATIONAL PAIN STRATEGY 2010

- Goal 1: People in pain as national health priority
- Goal 2: Empowered & knowledgeable consumers
- Goal 3: Informed & supported health professionals
- Goal 4: Timely access to best practice care
- Goal 5: Outcomes evaluated
- Goal 6: National pain research strategy
- Goal 7: Focus on prevention & work participation



Painaustralia

- Cost of Pain Report launched
 - Deloitte Access Economics
 - Funded by Seqirus
 - 2018 3.24 million Australians with CNCP; 68.3% working age
 - Cost of \$73.2 billion per annum
 - Call for GP education, multidisc care
- National Strategic Action Plan
 - Endorsed by Federal govt & opposition
 - \$2.5M for pain education



National Advisory Council on Pain \$1M Item number review:
consultation &
multidisciplinary
care

Regulation

Subsidised medication

MEDICARE BENEFITS
SCHEDULE

PHARMACEUTICAL BENEFITS SCHEME

THERAPEUTIC GOODS ADMINISTRATION

STATE HEALTH
DEPARTMENTS

Commonwealth approval, indications (eg. fentanyl patches for CNCP), PI, CMI, recommendations to sponsors about pack size

Authority for individual cases Real time monitoring





Thank you